A safety communication discouraging use of power morcellation during hysterectomy or myomectomy for fibroids has been issued by the Food and Drug Administration (FDA) because of concern about risk of inadvertent spread of unsuspected cancer to abdominal and pelvic cavities.
A safety communication discouraging use of power morcellation during hysterectomy or myomectomy for fibroids has been issued by the Food and Drug Administration (FDA) because of concern about risk of inadvertent spread of unsuspected cancer to abdominal and pelvic cavities. The FDA’s recommendations to health care providers include not using the technology in women with suspected or known uterine cancer. Recommendations to women undergoing laparoscopic hysterectomy or myomectomy include asking your health care provider if power morcellation will be performed and if so, why it is considered the best treatment option for you.
Perspective from Deputy Editor Jon I. Einarsson, MD, PhD, MPH
“The FDA safety communication discourages use of laparoscopic power morcellation and indicates that the practice will be further evaluated by the Obstetrics and Gynecological Medical Devices Panel. Physicians are encouraged to consider all available treatment options and to discuss the risks and benefits of all options with their patients. Several institutions have already stopped or significantly restricted the use of open power morcellation due to concerns about the spread of undiagnosed malignancy.
In our experience, in-bag morcellation is a feasible approach to laparoscopic specimen retrieval which may significantly limit potential spread of occult malignancy during laparoscopy. In-bag morcellation is being actively investigated by several centers at the present time because more information is needed about the safety and efficacy of this approach. Alternative methods of tissue extraction that do not involve traditional morcellators are also being developed. I suspect that this field will continue to evolve very rapidly during the next few months.”
For more coverage from Contemporary OB/GYN on morcellation, read our March cover story.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More